DIOD, Russian pharmaceutical producer has completed the transaction on sale of Orvirem product brand portfolio, including trademarks and other product related IP rights, to Alvogen, a leading international pharmaceutical company.
Orvirem is a fast-growing high-marginal Rx flu antiviral drug in form of syrup for children.
The divestiture of Orvirem will allow DIOD to focus on its core segment, food supplements production business. The new product fits Alvogen portfolio in Russia very well and further strengthens and diversifies its branded portfolio.
BIC Securities acted as exclusive financial adviser to DIOD during the entire sale process.
The terms of the transaction are not disclosed.
Return to archive